These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 32880853)
1. Emergency Use Authorization for Remdesivir and Its Potential Implications. Ochoa Chaar CI; Makuch R Ther Innov Regul Sci; 2021 Mar; 55(2):270-271. PubMed ID: 32880853 [No Abstract] [Full Text] [Related]
2. Have we found the panacea to COVID-19 with remdesivir, an old but newly packaged drug? Thalha AMM; Lee YY; Besari A; Omar SFS J R Coll Physicians Edinb; 2020 Jun; 50(2):159-161. PubMed ID: 32568289 [No Abstract] [Full Text] [Related]
4. COVID-19 updates: Remdesivir (Veklury) in high-risk outpatients with COVID-19. Med Lett Drugs Ther; 2022 Feb; 64(1644):31-32. PubMed ID: 35171898 [No Abstract] [Full Text] [Related]
5. Assessing the evidence on remdesivir. Trøseid M; Hites M; Barratt-Due A; Ader F; Yazdanpanah Y Lancet Infect Dis; 2021 Dec; 21(12):1630-1631. PubMed ID: 34838222 [No Abstract] [Full Text] [Related]
6. Remdesivir: a pendulum in a pandemic. Schwartz IS; Heil EL; McCreary EK BMJ; 2020 Nov; 371():m4560. PubMed ID: 33234523 [No Abstract] [Full Text] [Related]
7. Remdesivir for patients with COVID-19. Wu PE; Morris AM CMAJ; 2021 Jan; 193(4):E125. PubMed ID: 33408097 [No Abstract] [Full Text] [Related]
8. Remdesivir (Veklury) for the Treatment of COVID-19 in Hospitalized Patients. Odeti S; Yellepeddi VK Am Fam Physician; 2021 Sep; 104(3):311-312. PubMed ID: 34523893 [No Abstract] [Full Text] [Related]
9. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2). Qaseem A; Yost J; Etxeandia-Ikobaltzeta I; Abraham GM; Jokela JA; Forciea MA; Miller MC; Humphrey LL; ; Centor RM; Andrews R; Haeme R Ann Intern Med; 2021 May; 174(5):673-679. PubMed ID: 33560862 [TBL] [Abstract][Full Text] [Related]
10. Commentary: "Emergency Use Authorization for Remdesivir: A Pediatric Perspective". Noel GJ; Connor E Pediatr Infect Dis J; 2020 Sep; 39(9):e234. PubMed ID: 32639464 [No Abstract] [Full Text] [Related]
11. Clinical pharmacodynamics of obeldesivir versus remdesivir. Faghihi I; Yan VC Antimicrob Agents Chemother; 2024 Sep; 68(9):e0096924. PubMed ID: 39133123 [No Abstract] [Full Text] [Related]
12. Remdesivir improved time to recovery in adults hospitalized with COVID-19 and lower respiratory tract involvement. Paladugu S; Donato AA Ann Intern Med; 2020 Jul; 173(2):JC4. PubMed ID: 32687756 [TBL] [Abstract][Full Text] [Related]
13. Update Alert 2: Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2). Qaseem A; Yost J; Etxeandia-Ikobaltzeta I; Abraham GM; Jokela JA; Miller MC; Forciea MA; Humphrey LL; Ann Intern Med; 2021 Dec; 174(12):W116-W117. PubMed ID: 34606308 [No Abstract] [Full Text] [Related]
14. Audio Interview: New Data on Remdesivir in Covid-19. Rubin EJ; Baden LR; Morrissey S N Engl J Med; 2020 May; 382(22):e94. PubMed ID: 32459948 [No Abstract] [Full Text] [Related]
15. Remdesivir: Critical Clinical Appraisal for COVID 19 Treatment. Chatterjee S Drug Res (Stuttg); 2021 Mar; 71(3):138-148. PubMed ID: 33124007 [TBL] [Abstract][Full Text] [Related]
16. USA stockpiling of remdesivir: How should the world respond? Dawoud D; Chalkidou K; Sullivan R; Ruiz FJ; Adler A J Comp Eff Res; 2020 Dec; 9(18):1243-1246. PubMed ID: 33274643 [TBL] [Abstract][Full Text] [Related]
17. [Remdesivir for patients with severe COVID-19]. Augustin M; Hallek M; Nitschmann S Internist (Berl); 2020 Jun; 61(6):644-645. PubMed ID: 32333086 [No Abstract] [Full Text] [Related]
18. Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients. Wu TY; Chen PY; Wang JT; Liu WD; Chen YC; Chang SC J Antimicrob Chemother; 2024 May; 79(5):1196-1200. PubMed ID: 38538154 [No Abstract] [Full Text] [Related]
19. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1). Qaseem A; Yost J; Etxeandia-Ikobaltzeta I; Abraham GM; Jokela JA; Forciea MA; Miller MC; Humphrey LL; ; Centor RM; Andrews R; Haeme R; Kansagara DL; Marcucci M Ann Intern Med; 2021 Feb; 174(2):229-236. PubMed ID: 33017175 [TBL] [Abstract][Full Text] [Related]